Search


 
Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 14 (Search time: 0.001 seconds).
Item hits:
First PublishedTitleAuthor(s)Type
Oct-2009Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.Rudinskiy, N; Kaneko, YA; Beesen, AA; Gokce, O; Régulier, E; Déglon, N; Luthi-Carter, RJournal Article
1-Aug-2007Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.Kuhn, A; Goldstein, DR; Hodges, A; Strand, AD; Sengstag, T; Kooperberg, C; Becanovic, K; Pouladi, MA; Sathasivam, K; Cha, JH; Hannan, AJ; Hayden, MR; Leavitt, BR; Dunnett, SB; Ferrante, RJ; Albin, R; Shelbourne, P; Delorenzi, M; Augood, SJ; Faull, RL; Olson, JM; Bates, GP; Jones, L; Luthi-Carter, RJournal Article
15-Jan-2005Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.Zucker, B; Luthi-Carter, R; Kama, JA; Dunah, AW; Stern, EA; Fox, JH; Standaert, DG; Young, AB; Augood, SJJournal Article
Feb-2006Capucin: a novel striatal marker down-regulated in rodent models of Huntington disease.de Chaldée M; Brochier, C; Van de Vel A; Caudy, N; Luthi-Carter, R; Gaillard, MC; Elalouf, JMJournal Article
15-May-2007Modulation of nucleosome dynamics in Huntington's disease.Stack, EC; Del Signore SJ; Luthi-Carter, R; Soh, BY; Goldstein, DR; Matson, S; Goodrich, S; Markey, AL; Cormier, K; Hagerty, SW; Smith, K; Ryu, H; Ferrante, RJJournal Article
17-Oct-2008The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity.Jan, A; Gokce, O; Luthi-Carter, R; Lashuel, HAJournal Article
Apr-2009A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease.Zabel, C; Mao, L; Woodman, B; Rohe, M; Wacker, MA; Kläre, Y; Koppelstätter, A; Nebrich, G; Klein, O; Grams, S; Strand, A; Luthi-Carter, R; Hartl, D; Klose, J; Bates, GPJournal Article
Jan-2009Implication of the JNK pathway in a rat model of Huntington's disease.Perrin, V; Dufour, N; Raoul, C; Hassig, R; Brouillet, E; Aebischer, P; Luthi-Carter, R; Déglon, NJournal Article
Mar-2009Sustained effects of nonallele-specific Huntingtin silencing.Drouet, V; Perrin, V; Hassig, R; Dufour, N; Auregan, G; Alves, S; Bonvento, G; Brouillet, E; Luthi-Carter, R; Hantraye, P; Déglon, NJournal Article
Dec-2008Biological and potential therapeutic roles of sirtuin deacetylases.Taylor, DM; Maxwell, MM; Luthi-Carter, R; Kazantsev, AGJournal Article